Adverse Effect Of Isotichiin
Indications for use a reason to prescribe a medication or treatment, also known as
drug indication (Mosby s, pg 916, 2017). High risk neuroblastoma is an indication
of use for Unituxin (dinutuximab) (FDA, 2015). Desired effects the ability of a
drug to achieve the desired effect, also known as efficacy (Mosby s, pg 593, 2017).
Unituxin in combination with interleukin 2 (IL 2), granulocyte macrophage colony
stimulating factor (GM CSF), and 13 cis retionic acid (RA) showed that 73 percent
of the participants who received this combination were alive compared to 58
percent of those receiving the oral retinoid drug, isotretinoin (RA) (FDA, 2015).
Side Effects any reaction to or consequence of a medication or therapy (Mosby s, pg
... Show more content on Helpwriting.net ...
Signs or symptoms could include lumps in the abdomen, bone pain, bulging eyes,
dark circles around the eyes, swollen stomach, trouble breathing, weakness or
paralysis. Once neuroblastoma has been diagnosed, it has usually metastasized to
the lymph nodes, bones, bone marrow, and liver (NIH, n.d.). The therapeutic
classification of Unituxin (dinutuximab) is a monoclonal antibody, which is a type
of immunotherapy drug. Unituxin helps the body s immune system find and
destroy cancer cells. It is used along with other treatments, which include
chemotherapy, surgery, and radiation for children who have responded to previous
treatment (Simon, 2015). The indications of use for Unituxin are used in
combination with granulocyte macrophage colony stimulating factor (GM CSF),
interleukin 2 (IL 2) and 13 cis retinoic acid (RA), for the treatment of children with
high risk neuroblastoma who achieve at least a partial response to prior first line
multi agent, multimodality therapy (United (c), 2017). The available form of
Unituxin is 17.5 mg/mL (3.5 mg/mL) in a single use vial. Children and
Adolescents 17.5 mg/m2/dose as an IV infusion over 10 to 20 hours on scheduled
days for 5 cycles in combination with isotretinoin, sargramostim, and aldesleukin.
On cycles 1, 3, and 5: give sargramostim 250 mcg/m2/day subcutaneously (or as an
IV infusion over 2 hours) on days 1 to 14; dinutuximab on days 4, 5, 6, and 7; and
isotretinoin 160 mg/m2/day PO in 2 divided doses rounded